ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM)
To confirm the result of previous Phase I/II and phase II clinical trials, this trial is to test the efficacy and safety of ADCTA immunotherapy plus the standard therapy in comparison with standard therapy alone in patients with recurrent GBM.
Glioblastoma Multiforme
BIOLOGICAL: Autologous Dendritic Cell/Tumor Antigen, ADCTA
Overall Survival (OS), The duration will be calculated from the date of randomization until the date of death from any cause, assessed up to 60 months.
Progression-free Survival (PFS), The duration will be calculated from the date of randomization until the date of first documented progression according to the modified RANO or date of death from any cause, whichever came first,assessed up to 60 months.|Progression-free Survival at 6 months (PFS6), The duration will be calculated from the date of randomization to the date of the sixth month.|1 and 2-year Survival Rate, The duration will be calculated from the date of randomization to the date of the first year and the second year.
To confirm the result of previous Phase I/II and phase II clinical trials, this trial is to test the efficacy and safety of ADCTA immunotherapy plus the standard therapy in comparison with standard therapy alone in patients with recurrent GBM.